Multiple Myeloma

Data reported on thalidomide, melphalan, and prednisone combination

Published in Drug Week, January 7th, 2005

Celgene Corp. (CELG) announced that data evaluating clinical results on the treatment of newly diagnosed multiple myeloma patients with an oral combination therapy consisting of melphalan, prednisone, and thalidomide (MPT) were presented at the American Society of Hematology 46th annual meeting, San Diego, California.

The study reported a statistically significant difference in event-free survival of 25.2 months versus 13.7 months (P<0.001) after a minimum of 6 months of treatment with melphalan, prednisone, and thalidomide versus melphalan and prednisone (MP) alone.

This phase II study reported clinical data in newly diagnosed multiple myeloma...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2005-01-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry